ICx Technologies, a developer of advanced technology solutions for homeland security and force protection, said it has inked a research study deal with Merck & Co., Inc. and Fred Hutchinson Cancer Research Center of Seattle.

The purpose of the study is to test and refine a set of protocols for detecting and recovering circulating nucleic acids from blood - a key early detector for cancer treatment - in order to support the development of an investigational cancer therapy. The study is being conducted by its La Jolla, California-based Biosystems unit with participation by the Hutchinson Center.

"We have a history of aggressive research and development expertise and we're pleased to work with Merck," said Hans Kobler, CEO, ICx. "By applying the rapid and data-rich molecular diagnosis technology developed for security applications, ICx is hoping to aid the development of a diagnostic tool to assist in the evaluation of cancer therapies."

ICx develops advanced technologies for effective security solutions. ICx sensors detect and identify chemical, biological, radiological, nuclear and explosive (CBRNE) materials. The company's surveillance products discern people and objects invisible to human senses and conventional cameras. ICx software and systems connect, command and control these security devices, while its intelligence and special-operations experts provide the unique insight that drives the company's innovation. ICx has manufacturing and research facilities in the United States, Canada and Europe.